Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of allogeneic sibling umbilical cord blood mononuclear cell infusion in children with cerebral palsy or cerebral disorders
jRCTa060200017Completed
- Start
- Oct 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of allogeneic sibling umbilical cord blood mononuclear cells in cerebral palsy (CP) and hypoxic-ischemic encephalopathy (HIE). Primary endpoint: Safety (acute infusion reactions, infections, graft versus host disease, other adverse events). Started Oct 2020; status: completed.
02
Drugs
allogeneic sibling umbilical cord blood mononuclear cells
03
Conditions
cerebral palsy (CP)hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on jRCTa060200017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTa060200017.